Health.Global Q1 FY27 Earnings Call — Analysis (NSE: HCG)
HCG starts FY27 with 13% revenue growth and 120 bps margin expansion as payor mix improves and newly commissioned North Bangalore hospital begins contributing; management reiterates mid-teens growth and lays out path to 25% EBITDA margins.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹695.1 Cr ( +13% YoY ) . New guidance — FY27 revenue growth mid-teens . New story: Payor mix improvement driving margin expansion .
Results
Q1FY27 consolidated revenue ₹695.1 Cr (+13% YoY); adjusted EBITDA ₹133.9 Cr (+20% YoY) with margins at 19.4% (+120 bps YoY) driven by non-institutional mix improving to 69% and deliberate reduction in low-margin therapies.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹695.1 Cr | +13% | yoy · Q1FY27 |
| Adjusted EBITDA | ₹133.9 Cr | +20% | yoy · Q1FY27 |
| Adjusted EBITDA margin | 19.4% | +120 bps | yoy · Q1FY27 |
| Patient volume growth | 11% | +na | yoy · Q1FY27 |
| ARPP growth | 2% | +na | yoy · Q1FY27 |
Guidance
Mid-teens revenue growth outlook maintained; EBITDA margin target of 21-22% in 2 years and 25% in 4-5 years; North Bangalore monthly EBITDA breakeven expected in FY27; FY27 maintenance capex ~₹100 Cr.
What management committed to
- HCG remains confident of delivering mid-teens revenue growth from existing centres including new ones. — mid-teens, FY27
- HCG targets an EBITDA margin of 21-22% in the next 2 years. — 21-22%, FY29
- HCG is confident of reaching 25% EBITDA margin in the next 4 to 5 years. — 25%, FY31
- HCG plans to add 65 operational beds in FY27. — 65 beds, FY27
- HCG plans to add 520 operational beds in FY28 and FY29. — 520 beds, FY29
- HCG plans to add 230 operational beds in FY30. — 230 beds, FY30
- North Bangalore hospital is expected to achieve a monthly EBITDA breakeven in FY27. — monthly breakeven, FY27
- Maintenance capex is likely to be approximately ₹100 Cr in FY27. — ₹100 Cr, FY27
Key themes
Payor mix shift and disciplined capacity buildout
How the narrative shifted
- Payor mix improvement driving margin expansion: Management emphasized deliberate shift from low-margin institutional to higher-value non-institutional revenues, resulting in 200 bps payor mix improvement and 120 bps margin expansion.
- Capacity expansion to capture oncology demand: Significant brownfield and greenfield bed additions planned through FY30 to leverage growing cancer incidence and HCG's brand, with 60% from lower-cost brownfield projects.
- New hospital ramp-up as margin catalyst: North Bangalore facility's strong initial traction and peak loss absorption this quarter position it as a key margin and growth driver over the next 3-4 years.
- Operating leverage from maturing centres: With 16 centres recording highest-ever quarterly revenue and broad-based volume growth, existing centres are demonstrating scale benefits and cost absorption.
- Strategic refocus post-Fertility exit: The completion of the Fertility business divestment and balance sheet strengthening via rights issue have sharpened HCG's oncology focus.
- Disciplined capital allocation: Rights issue proceeds used for debt repayment and increasing stake in Vizag hospital rather than aggressive M&A, indicating prudent use of capital.
Operational commentary
- North Bangalore Comprehensive Cancer Center commenced operations in May'26, recording ₹6.7 Cr revenue, 550+ new patient registrations and >300 admissions in Q1; peak EBITDA loss reached this quarter; MR-LINAC commissioned in July'26.
- Payor mix improved sequentially as non-institutional revenue grew 17% YoY, increasing its share from 67% to 69%, driven by deliberate reduction in low-margin institutional business.
- Strategic exit from Fertility business completed at end of June'26, sharpening focus on core oncology.
- Network added 121 operational beds during the quarter; pipeline of 65 beds in FY27, 520 beds in FY28-29, and 230 beds in FY30; ~60% brownfield projects.
- Clinical capabilities strengthened with new LINAC in Rajkot, 2 surgical robotic systems (Nashik, Bangalore CoE), and ongoing investments in CAR-T, BMT, and precision diagnostics.
- Cost optimization and productivity initiatives underway using automation, data analytics, and sales/marketing ramp-up to improve operating leverage and patient experience.
- 16 of 25 centres recorded their highest-ever quarterly revenues; South cluster grew 16%, West 9%, East 22%.
Analyst Q&A
Q. What were the utilization levels across the 3 clusters?
We actually do not give the utilization levels at this point in time, and this is only annual disclosure. We would be giving this information when presenting the March '27 financials.
Q. Can HCG at the consolidated level operate at 23-25% EBITDA margin in 2-3 years?
We are very confident that with the levers we have in place... we are in a very good position to meet the 24%, 25% EBITDA margins in the next few years. In the next 2 years we are looking at 21-22% margin.
Q. How much is the marketing spend as a percentage of revenue and is there a target?
It is today at 2.9% of our sales. We want to keep it around that mark... It will be in the 2.5% to 2.6% range longer term.
Q. What is the like-to-like revenue growth across the monthly revenue buckets?
I do not have that number right now, but we can offline connect with you and give you that.
Research and educational content only. Not investment advice.